Mount Sinai School of Medicine - Recruiting 18 years or older. - Comparison of Weight Loss Among Early Stage Breast Cancer Patients Post Chemotherapy: Nutrition Education in Combination With Weight Loss Acupuncture Vs. Nutrition Education Alone.
National Surgical Adjuvant Breast and Bowel Project (NSABP) - Recruiting 18 years or older. - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.
Alliance for Clinical Trials in Oncology - Recruiting 18 years or older. - Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
Xoft, Inc. - Recruiting 40 years or older. - A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoftr Axxentr eBxT System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer.
Roswell Park Cancer Institute - Recruiting 50 years or older. - Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer.
Novartis - Recruiting 18 years or older. - NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.
Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older. - A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer.
cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-associated Breast Cancer.
Eastern Cooperative Oncology Group - Recruiting 18 years or older. - A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer.
City of Hope Medical Center - Recruiting 19 years or older. - Phase II Prospective Open Label Single Arm Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Metastatic Breast Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A PHASE III, RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY +/-CHEMOTHERAPY IN PATIENTS WITH 1-3 POSITIVE NODES, HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE BREAST CANCER WITH RECURRENCE SCORE (RS) OF 25 OR LESS. RXPONDER: A CLINICAL TRIAL RX FOR POSITIVE NODE, ENDOCRINE RESPONSIVE BREAST CANCER.
AbbVie - Recruiting 18 years or older. - A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC).
Thomas Jefferson University - Recruiting 18 years or older. - An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer.
SOLTI Breast Cancer Research Group - Recruiting 18 years or older. - PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer.
Washington University School of Medicine - Recruiting 18 years or older. - A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells.
M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer.
Tata Memorial Hospital - Recruiting 18 years or older. - A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer.
M.D. Anderson Cancer Center - Recruiting 18 years or older. - Feasibility, Validation and Implementation of Genomic Testing for Chemotherapy and Endocrine Sensitivity of HER2 Negative Primary Invasive Breast Cancer (Clinical Stage I to III).
University of Arizona - Recruiting N/A or older. - A Pilot Study Of Estradiol Followed By Exemestane For Post-Menopausal Hormone Receptor Positive Metastatic Breast Cancer After Prior Failed Endocrine Therapy: Reversing Endocrine Resistance.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer.
3-dimensional conformal accelerated partial breast irradiation; brachytherapy; whole breast irradiation
University of Chicago - Recruiting 18 years or older. - A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Nab-paclitaxel, Abraxane) With or Without Mifepristone for Advanced Breast Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer.
Georgia Center for Oncology Research & Education - Recruiting 18 years or older. - Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer.